- Chief Scientific Officer at Fedora Pharmaceuticals, Inc.- Chief Scientific Officer at Brass Dome Ventures Ltd.- Advisor, Antimicrobial Resistance Steering Committee, Public Health Agency of Canada (PHAC)- Executive Board Member, Canadian Pandemic Preparedness Hub (CP2H)- Member of Science & Business Advisory Board, Li Ka Shin Alberta Virology Institute (LKSAVI)- Chair, Canadian Antimicrobial Resistance Coalition (CAIC)- Co-Chair, BioAlberta Board of Directors- Chair, Al Rashid Education Foundation (AREF), - Advises for or serves on several committees for a number of not-for-profit organizations.Dr. Salama has over 25 years drug discovery experience across several disciplines including the discovery and development of new antibacterial and antifungal agents. He also held several C-level positions in both the drug discovery and contract research sectors.Additionally, Dr. Salama is business development professional with over 20-year experience in strategic planning, evaluation of new business and scientific opportunities, partnership establishment and management, contract negotiations, as well as in-licensing and out-licensing of assets. He was actively involved in dozens of licensing and partnership agreements, including the licensing of Fedora’s Beta-lactamase inhibitors to F. Hoffman La Roche in a US$750 million license deal.Dr. Salama received his Ph.D. in Microbiology from the University of Salford, UK, and published over 50 original research articles and presentations at international congresses. He is also an inventor on several original patents in the anti-infective and anti-inflammatory disease areas.